(Q36040853)

English

Drugs to suppress cough

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

Drugs to suppress cough (English)

1 reference

Europe PubMed Central

11 August 2017

author name string

Chung KF

1

1 reference

Europe PubMed Central

11 August 2017

language of work or name

0 references

publication date

1 January 2005

1 reference

Europe PubMed Central

11 August 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

11 August 2017

14

1 reference

Europe PubMed Central

11 August 2017

1

1 reference

Europe PubMed Central

11 August 2017

19-27

1 reference

Europe PubMed Central

11 August 2017

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Angiogenesis and arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Basic fibroblast growth factor stimulates osteoclast recruitment, development, and bone pit resorption in association with angiogenesis in vivo on the chick chorioallantoic membrane and activates isolated avian osteoclast resorption in vitro

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

VEGFs, receptors and angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

VEGF-receptor inhibitors for anti-angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Requirement of vascular integrin alpha v beta 3 for angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Immunohistochemical localisation of protein tyrosine kinase receptors Tie-1 and Tie-2 in synovial tissue of rheumatoid arthritis: correlation with angiogenesis and synovial proliferation

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Autocrine/paracrine role of the angiopoietin-1 and -2/Tie2 system in cell proliferation and chemotaxis of cultured fibroblastic synoviocytes in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Targeting HIF-1 for cancer therapy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

New anticancer strategies targeting HIF-1.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Cyclooxygenase-2 and prostaglandins in articular tissues

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

The role of COX-2 in angiogenesis and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Matrix metalloproteinases and angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

The regulation of neovascularization of matrix metalloproteinases and their inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Rheumatoid synovial endothelial cells secrete decreased levels of tissue inhibitor of MMP (TIMP1).

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Matrix metalloproteinase-19 in capillary endothelial cells: expression in acutely, but not in chronically, inflamed synovium

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Regulation of matrix metalloproteinases: an overview

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Evidence of IL-18 as a novel angiogenic mediator

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

The functional role of the ELR motif in CXC chemokine-mediated angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Kringle structures and antiangiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

The angiogenesis inhibitor protease-activated kringles 1–5 reduces the severity of murine collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Inhibition of arthritis by systemic administration of endostatin in passive murine collagen induced arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

A reevaluation of integrins as regulators of angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Effects of paclitaxel on cultured synovial cells from patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT).

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Angiogenesis inhibition suppresses collagen arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF).

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Effects of PTK787/ZK222584, a Tyrosine Kinase Inhibitor, on the Growth of a Poorly Differentiated Thyroid Carcinoma: An Animal Study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor in colorectal cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Advances in the Genetic Screening, Work-up, and Treatment of Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Synergistic effects of thalidomide and poly (ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Thalidomide a promising new treatment for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Neutralization of Vascular Endothelial Growth Factor Prevents Collagen-Induced Arthritis and Ameliorates Established Disease in Mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.19

21 January 2018

Identifiers

10.1517/13543784.14.1.19

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36040853&oldid=1612988826"